Peter Kulesza
Impact in
- Oncology top 5%
- PARP inhibition in cancer therapy
- Cancer Research top 5%
- NF-κB Signaling Pathways
Papers in
-
- Lung Cancer Treatments and Mutations 5
- Sarcoma Diagnosis and Treatment 1
- Oncology 8
- Pancreatic and Hepatic Oncology Research 4
- Colorectal Cancer Treatments and Studies 3
- HER2/EGFR in Cancer Research 2
- Co-authors
- Michael R. Lieber (3 shared papers)Ulf Grawunder (2 shared papers)Kenneth M. Murphy (1 shared paper)Jeanne Magram (1 shared paper)Mark Cleveland (1 shared paper)Theresa L. Murphy (1 shared paper)Matthias Wilm (1 shared paper)Matthias Mann (1 shared paper)
- Journals
- Diagnostic Cytopathology (4 papers)Cancer Research (3 papers)Journal of Biological Chemistry (2 papers)American Journal of Clinical Pathology (1 paper)Molecular Cancer Therapeutics (1 paper)
- Partner nations
- United StatesGermanyPhilippines
In The Last Decade
Peter Kulesza
23 papers receiving 1.9k citations
Peter Kulesza's Hit Papers
Peers
Comparison fields: 5 of 93
- Oncology 626
- Cancer Research 315
- Immunology 445
- Molecular Biology 965
- Pulmonary and Respiratory Medicine 215
Countries citing papers authored by Peter Kulesza
This map shows the geographic impact of Peter Kulesza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Kulesza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Kulesza more than expected).
Fields of papers citing papers by Peter Kulesza
This network shows the impact of papers produced by Peter Kulesza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Kulesza. The network helps show where Peter Kulesza may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Kulesza, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells Hit paper breakdown → | 1997 | 559 |
| 2 | 1995 | 456 | |
| 3 | 1998 | 135 | |
| 4 | 2006 | 96 | |
| 5 | 2005 | 91 | |
| 6 | 2008 | 75 | |
| 7 | 2009 | 69 | |
| 8 | 2008 | 56 | |
| 9 | 2010 | 54 | |
| 10 | 2007 | 44 | |
| 11 | 2010 | 43 | |
| 12 | 2013 | 34 | |
| 13 | 2011 | 34 | |
| 14 | 2008 | 32 | |
| 15 | 2006 | 28 | |
| 16 | 2006 | 27 | |
| 17 | 2002 | 20 | |
| 18 | 1994 | 16 | |
| 19 | 2011 | 15 | |
| 20 | 2006 | 13 |
About Peter Kulesza
Peter Kulesza is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Gastroenterology, having authored 23 papers that have together received 1.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (5 papers), Pancreatic and Hepatic Oncology Research (4 papers), DNA Repair Mechanisms (3 papers), Cancer Genomics and Diagnostics (3 papers), Colorectal Cancer Treatments and Studies (3 papers), Gastrointestinal Tumor Research and Treatment (3 papers), HER2/EGFR in Cancer Research (2 papers) and Sarcoma Diagnosis and Treatment (1 paper). The work is most often cited by research in Oncology (626 citations), Cancer Research (315 citations), Immunology (445 citations), Molecular Biology (965 citations) and Pulmonary and Respiratory Medicine (215 citations). Peter Kulesza has collaborated with scholars based in United States, Germany and Philippines. Frequent co-authors include Michael R. Lieber, Ulf Grawunder, Kenneth M. Murphy, Jeanne Magram, Mark Cleveland, Theresa L. Murphy, Matthias Wilm, Matthias Mann, Thomas E. Wilson and Xiantuo Wu. Their work appears in journals such as Diagnostic Cytopathology, Cancer Research, Journal of Biological Chemistry, American Journal of Clinical Pathology and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.